Background
Breast carcinoma is considered to be one of the main causes of cancer mortality. Assessment of the risk of development of invasive breast cancer has become a significant problem. In the last decade, screening programs have been intensified since mammographic screening significantly contributes on breast cancer mortality [
1,
2]. The major aim of these programs is the detection of breast carcinomas in earlier and probably better curable stage [
3]. In the past 20 years, concomitant with the wide use of screening mammography, the incidence of ductal carcinoma
in situ (DCIS) has risen dramatically, in asymptomatic women to 20-25% of all screening detected breast cancers [
4]. Therefore, the mammographically diagnosed non-palpable breast carcinomas are increasingly considered as a unique entity of major clinical interest. Non-palpable breast carcinomas consists a heterogeneous group of lesions with variable findings and different prognosis. Mammographically detected density is a risk factor for breast cancer and is attributed to alterations in the composition of breast tissue [
5,
6]. Previous studies seeking to understand the biological basis of mammographic density (MD) have focused on associations with epithelial and stromal changes [
7,
8]. Another mammographic finding of higher risk than tissue density for breast cancer is malignant-appearing microcalcifications (MAMCs), which are associated with
in situ and invasive breast carcinomas in asymptomatic women [
9]. MAMCs are the primary indication for approximately 50% of the breast biopsies carried out for non-palpable mammographic abnormalities, although they do not always represent malignancy [
10].
A wide range of prognostic markers have been proposed for non-palpable breast carcinomas. The clinically available markers such as histological type, size, auxiliary node involvement and cytological grading are not sufficient, considering the biological complexity of this clinical entity [
11]. Several biological markers such as estrogen receptor alpha (ERα), progesterone receptor (PR), and the ErbB family of receptor tyrosine kinases have been evaluated by means of immunohistochemistry in non-palpable breast carcinomas and found to correlate with mammographic findings of higher risk such as MAMCs [
12,
13]. Estrogens contribute to the initiation and promotion of cancer through triggering the proliferation of breast epithelium and stroma. Consequently they increase the changes of mutation in rapidly proliferating epithelium and those effects accumulate with increasing cumulative exposure to estrogens [
14]. The over-expression of c-erbB2 (HER-2/neu) is associated with more aggressive tumor behavior [
15].
Although breast cancer is a direct manifestation of alterations in the expression of multiple genes and cellular pathways within the cancer cell, it is now recognized that perturbations in stromal-epithelial interactions also influence tumorigenesis and progression through direct effects on growth factor-induced signaling pathways and indirect effects mediated through cell adhesion and structure [
8,
16,
17].
Several studies have demonstrated abnormal expression of the matrix-secreted proteoglycans versican and decorin in various cancer types such as prostate [
18,
19], breast [
20,
21], gastric [
22], colorectal [
23,
24], ovarian [
25], pancreatic [
26], laryngeal [
27,
28] and testicular tumors [
29]. Versican is synthesized mainly by stromal cells and is capable to regulate tumor cell growth and motility. Versican may facilitate the local expansion of cancer cells and, subsequently, the invasion and formation of distant metastases by decreasing cell-matrix adhesion, sufficient to promote cancer cell migration through the extracellular matrix [
30‐
32]. This notion is supported by observations that relapse in women with stage I node-negative breast cancer is related to the level of versican accumulated in peritumoral stroma [
21] and the increased levels of peritumoral versican are also predictive of poor prognosis in patients with early-stage prostatic cancer [
18]. In contrast, decorin, which is mainly over-expressed by activated fibroblasts in various cancer types, is considered to be a tumor suppressor proteoglycan [
18,
22‐
24,
26‐
29,
32]. Others have previously shown that matrix proteoglycans lumican and decorin are abundant components of breast tissue stroma and that altered expression of lumican and decorin is associated with tumor progression and outcome [
33‐
35]. These proteoglycans are important for stromal integrity through their implication in fibrillar collagen cross linking. Decorin is also a powerful regulator of growth factor-mediated signaling [
32].
We therefore wished to examine the relationship between mammographic findings suggestive of malignancy in non-palpable breast carcinomas and the expression of stromal proteoglycans versican and decorin, to establish whether the increased risk attributed to these findings might reflect stromal alterations. The expression of both proteoglycans was correlated with tumor characteristics and established biomarkers of the disease to evaluate their implication in breast cancer biology. Both proteoglycans were accumulated in MD and MAMCs although decorin was most likely associated with tissue fibrosis and matrix deposition. Versican was specifically accumulated in MD and MAMCs in the presence of malignant transformation and was significantly correlated with increased tumor grade and invasiveness. The over-expression of both proteoglycans is associated with the presence of ERα and PR in tumor cells in MAMCs.
Discussion
An improved understanding of factors influencing changes in MD and the formation of MAMCs would improve their value and practical application in risk assessment in non-palpable breast cancer. Although both MD and microcalcifications have been shown to be influenced by various parameters [
7,
8,
12,
13,
39,
40], the biological basis underlying these tissue alterations is largely unknown [
41]. Studies have shown that both stromal architecture and composition can exert an important influence on normal epithelial homeostasis [
16,
17,
42], and somatic mutations can be identified in the stromal compartment of breast tumors independently of mutations in the neoplastic epithelium [
43,
44]. These observations are in accordance with the concept that stromal alterations might not always be 'reactive' but might sometimes play an initial 'landscaping' role in breast carcinogenesis, as has been proposed for the colon [
45]. Several studies have shown the relationship between increased MD and specific epithelial lesions [
7,
8,
39,
46], whereas others have also noted a close association with stromal changes and suggest that MD correspond more directly to alterations in stromal composition including decorin [
8,
38,
40]. In this study, we found a significant accumulation of decorin in normal breast tissues that are characterized by increased MD and MAMCs. A similar increase in decorin expression was noticed to the tumor stroma in non-palpable breast carcinomas with high MD and MAMCs. Decorin directly binds to collagen and affects fibrillogenesis and fibril spacing that are important aspects for stromal architecture and properties [
32,
47]. Taken into consideration our data and the previous observations that increased MD is associated with higher collagen density and extended fibrosis [
38], it is likely that the deposition of decorin in MD and MAMCs might be associated with tissue fibrosis and matrix deposition. Furthermore, the observation that decorin levels are significantly higher in
in situ compared to invasive breast carcinomas with MAMCs suggests that up-regulation of decorin prevents tumor spread. This is consistent with the observation that decorin inhibits various signaling cascades of the ErbB family of receptor tyrosine kinases [
32,
47] and low levels of decorin expression are associated with poor outcome in primary invasive tumors [
34].
In contrast, the expression of versican is specifically up-regulated only in breast tissues with high MD and MAMCs, which are associated with malignant transformation. The deposition of versican in tumor stroma is significantly higher in MAMCs, a mammographic finding that is associated with higher risk for breast cancer than increased MD alone. The accumulation of versican in non-palpable carcinomas is related to higher tumor grade and the presence of invasive disease in lesions of both MD and MAMCs. This supports further the notion of a positive role for versican in tumor growth and progression in breast cancer. The increased accumulation of versican in tumor stroma by mammary fibroblasts is correlated with relapse in women with node-negative breast cancer [
21]. Additional evidences in early-stage prostatic cancer [
18] and ovarian cancer [
25] supports the view that versican deposition is associated with progression of disease. Versican is thought to be an anti-adhesion molecule and this activity resides in the G1 domain of versican [
30‐
32]. The interaction of versican with several binding molecules such as hyaluronan and CD44 promotes expansion of the pericellular matrix [
48]. These complexes increase the viscoelastic nature of the pericellular matrix, creating a highly malleable extracellular environment which supports a cell shape change necessary for cancer cell proliferation and migration [
30‐
32]. Furthermore, versican could influence cell proliferation by acting as a mitogen itself through the epidermal growth factor (EGF) sequences in the G3 domain [
30,
32], whereas versican G3 domain appears to be important in local and systemic tumor invasiveness of human breast cancer affecting both tumor cell survival and spread but also angiogenesis [
49].
In postmenopausal women, MD is directly associated with circulating levels of estradiol [
50] supporting a role of circulating hormones in breast cancer risk. Furthermore, aromatase the key enzyme converting testosterone to estradiol is increased in mammographically dense tissue in both the stroma and epithelium as demonstrated by immunohistochemistry [
51]. We found that the elevated expression of decorin and versican by stromal fibroblasts in non-palpable breast carcinomas with MAMCs is positively correlated with the higher expression of ERα and PR by tumor cells. The expression of estrogen receptors in tumor cells most likely associate with increased levels of estrogens that regulate the growth of tumor cells in hormone-dependent breast cancer. Estradiol has found to play a key role in the expression of proteoglycans in breast cancer cells via its action to ERα [
52]. Published data demonstrate that the biosynthesis of both proteoglycans is positively regulated by estrogens in osteoblastic cells [
53] and normal endometrial stromal cells [
54]. Possibly estrogens mainly produced locally by stromal fibroblasts in early stages of breast carcinogenesis drive through paracrine action tumor growth and through autocrine mechanisms the biosynthesis of versican and decorin by themselves. The expression of these proteoglycans is also regulated by various growth factors and cytokines present in increased amounts in the microenvironment of breast cancer lesions [
30‐
32].
MAMCs are suggested to be a consequence of an active secretory process by the tumor cells [
55]. Malignant mammary cells could express matrix molecules that would create an appropriate microenvironment to trigger calcifications by hydroxyapatite formation [
55]. Benign or proliferative breast disease is associated with the deposition of oxalate calcifications, whereas hydroxyapatite crystals are related to invasive breast cancer [
55]. Proteoglycans bind to hydroxyapatite and are involved in the calcification process acting either as promoters or inhibitors [
56,
57]. Decorin and biglycan are involved in the mineralization process and are required for normal bone development [
58]. One hypothesis for the role of decorin in mineralization is that its modulation of collagen fibrillogenesis in the extracellular matrix indirectly affects hydroxyapatite crystal growth [
59]. Decorin over-expression is also associated with intracellular calcification in epithelial cells [
60]. The intracellular calcification may be a potential origin for pathologic calcification in breast cancer. Hydroxyapatite crystals stimulate mitogenesis and up-regulate the production of a variety of matrix metalloproteinases in malignant mammary cells and fibroblasts that mediate the degradation of the basement membrane and the surrounding matrix thus leading to the formation of distant metastases[
61‐
63].
A possible scenario for the involvement of both proteoglycans in breast cancer progression may involve the accumulation of both versican and decorin by stromal fibroblasts in response to estrogens, growth factors and cytokines. The accumulated versican in the tumor stroma supports tumor growth and metastasis. Decorin is directly involved in the formation of a collagenous rich stroma associated with MD and may together with versican facilitate the formation of hydroxyapatite microcalcifications. In this process, stromal fibroblasts may be also involved. They over-express versican and decorin that may promote intracellular calcification. Hydroxyapatite crystals together with growth factors produced by cancer cells are capable to trigger cancer and stromal cell proliferation and up-regulation of synthesis of matrix degrading enzymes facilitating cancer cell spread.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
SSS carried out the immunoassays, performed the statistical analysis and helped to draft the manuscript, VTL carried out and evaluated the immunohistochemistry and helped to draft the manuscript, PR performed the histological and immunohistochemical evaluation and combined the figures, ELK performed and evaluated the mammographic screening, KD evaluated the immunostainings and combined the figures, HPK participated in the design of the study and helped to draft the manuscript, NKK participated in the design of the study and helped to draft the manuscript, ADT conceived of the study, participated in its design and coordination in the statistical analysis and to draft the manuscript. All authors read and approved the final manuscript.